Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States

by | Feb 22, 2022 | Cancer (blood), Publication

Authors: Levy M, Xie L, Wang Y, Neumann F, Srivastava S, Naranjo D, Xu J, Zhang Q, Dalal M Abstract Introduction: In this real-world study, the incidence of cardiovascular events (CV) including major adverse cardiac events (MACE), arterial occlusive events (AOE), and...

Time to next treatment, healthcare resource utilization, and costs associated with ibrutinib use among US veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world retrospective analysis

by | Oct 13, 2020 | Cancer (blood), Publication

Abstract Authors: Qing Huang, Sujana Borra, Jieni Li, Li Wang, Sulena Shrestha, Murali Sundaram, Nora Janjan  Background: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common adult leukemia, accounting for ≈ 37% of all leukemias in the...

Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data

by | Oct 2, 2020 | Cancer (blood), Hematology, Publication

Abstract Authors: Shreekant Parasuraman, Jingbo Yu, Dilan Paranagama, Sulena Shrestha, Li Wang, Onur Baser, Robyn Scherber Background: Patients with polycythemia vera (PV) have a substantial risk of thrombotic events (TEs). The objective of the present analysis...